Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Oct 2021

Frikha Rim, Turki Fatma, Kassar Olfa, Elloumi Moez, Kamoun Hassen

Abstract excerpt

INTRODUCTION: Diagnoses of myeloproliferative disorder is based on molecular marker. Chronic Myeloid Leukemia and Myeloproliferative neoplasms were considered mutually exclusive and co-existence of BCR/ABL1 and JAK2 mutation is a rare phenomenon. CASE REPORT: Here, we present two cases of co-existence of BCR-ABL and JAK2V617F positivity. We characterize the course of the disease, mainly the minimal residual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33567976
DOI: 10.1177/1078155221991646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?PMID 33567976Read ↗

Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combinationSemantic proximity Read ↗

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the LiteratureSemantic proximity Read ↗

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.Semantic proximity Read ↗

[Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].Semantic proximity Read ↗

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?Semantic proximity Read ↗

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.Semantic proximity Read ↗

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilitiesSemantic proximity Read ↗

Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.Semantic proximity Read ↗

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.Semantic proximity Read ↗

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.Semantic proximity Read ↗

BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.Semantic proximity Read ↗

A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.